Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disoproxil

- PMLiVE

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Sanofi Genzyme’s Lemtrada and Pfizer's Xeljanz receive label restrictions

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

- PMLiVE

Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Meanwhile J&J partnered Crohn's drug flops in phase 2

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

New hires at Bayer, Eisai and Accord Healthcare

The latest movers in pharma

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links